MEDP Medpace Holdings Inc

Price (delayed)

$153.89

Market cap

$5.18B

P/E Ratio

27.48

Dividend/share

N/A

EPS

$5.6

Enterprise value

$5.24B

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate ...

Highlights
MEDP's revenue is up by 27% year-on-year and by 6% since the previous quarter
The net income has increased by 25% YoY and by 10% from the previous quarter
Medpace Holdings's quick ratio has shrunk by 54% QoQ and by 52% YoY
Medpace Holdings's equity has decreased by 37% from the previous quarter and by 30% YoY

Key stats

What are the main financial stats of MEDP
Market
Shares outstanding
33.65M
Market cap
$5.18B
Enterprise value
$5.24B
Valuations
Price to earnings (P/E)
27.48
Price to book (P/B)
8.96
Price to sales (P/S)
4.43
EV/EBIT
23.94
EV/EBITDA
20.4
EV/Sales
4.32
Earnings
Revenue
$1.21B
EBIT
$218.7M
EBITDA
$256.76M
Free cash flow
$221.24M
Per share
EPS
$5.6
Free cash flow per share
$6.34
Book value per share
$17.17
Revenue per share
$34.75
TBVPS
$18.37
Balance sheet
Total assets
$1.34B
Total liabilities
$739.33M
Debt
$141.62M
Equity
$605.02M
Working capital
-$223.46M
Liquidity
Debt to equity
0.23
Current ratio
0.61
Quick ratio
0.53
Net debt/EBITDA
0.23
Margins
EBITDA margin
21.2%
Gross margin
28.7%
Net margin
16.5%
Operating margin
17.7%
Efficiency
Return on assets
13.2%
Return on equity
24.2%
Return on invested capital
258.2%
Return on capital employed
28.6%
Return on sales
18%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MEDP stock price

How has the Medpace Holdings stock price performed over time
Intraday
1.69%
1 week
13.69%
1 month
15.43%
1 year
-13.53%
YTD
-29.29%
QTD
-5.93%

Financial performance

How have Medpace Holdings's revenue and profit performed over time
Revenue
$1.21B
Gross profit
$348.41M
Operating income
$215.22M
Net income
$199.85M
Gross margin
28.7%
Net margin
16.5%
MEDP's revenue is up by 27% year-on-year and by 6% since the previous quarter
The net income has increased by 25% YoY and by 10% from the previous quarter
The operating income has increased by 20% year-on-year and by 8% since the previous quarter
MEDP's gross profit is up by 19% year-on-year and by 6% since the previous quarter

Growth

What is Medpace Holdings's growth rate over time

Valuation

What is Medpace Holdings stock price valuation
P/E
27.48
P/B
8.96
P/S
4.43
EV/EBIT
23.94
EV/EBITDA
20.4
EV/Sales
4.32
The EPS is up by 25% YoY and by 11% QoQ
The P/E is 24% lower than the last 4 quarters average of 36.3 and 18% lower than the 5-year quarterly average of 33.6
MEDP's price to book (P/B) is 91% higher than its 5-year quarterly average of 4.7 and 9% higher than its last 4 quarters average of 8.2
Medpace Holdings's equity has decreased by 37% from the previous quarter and by 30% YoY
MEDP's revenue is up by 27% year-on-year and by 6% since the previous quarter
MEDP's price to sales (P/S) is 26% less than its last 4 quarters average of 6.0 but 11% more than its 5-year quarterly average of 4.0

Efficiency

How efficient is Medpace Holdings business performance
MEDP's ROIC is up by 43% YoY but it is down by 5% QoQ
The company's return on equity rose by 21% YoY and by 19% QoQ
Medpace Holdings's return on assets has increased by 12% QoQ and by 11% YoY
The ROS is down by 4.8% YoY

Dividends

What is MEDP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MEDP.

Financial health

How did Medpace Holdings financials performed over time
The company's total assets is 82% higher than its total liabilities
Medpace Holdings's quick ratio has shrunk by 54% QoQ and by 52% YoY
Medpace Holdings's current ratio has shrunk by 51% QoQ and by 49% YoY
The debt is 77% smaller than the equity
MEDP's debt to equity has surged by 77% year-on-year and by 64% since the previous quarter
Medpace Holdings's equity has decreased by 37% from the previous quarter and by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.